Remarkably, models predicting OncotypeDX recurrence score and Prosigna risk of recurrence score shared many CNA regions with RB-LOH signature, indicating these two clinical assays contain features of tumor proliferation rates, which is known11,27 (Fig. 3j, k). Here, RB1 is linked to neoplasm.